Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 6/20 | 0.32 |
| ▸ | CNR1 | P21554 | 4/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10555642 | 1.00 | LMNA (0.36) | LMNAMAPK1HTTCNR2CNR1 | |
| SCHEMBL4894326 | 0.98 | LMNA (0.35) | LMNAMAPK1HTTCNR2CNR1 | |
| SCHEMBL27535742 | 0.98 | LMNA (0.36) | LMNAMAPK1HTTCNR2CNR1 | |
| SCHEMBL6744050 | 0.96 | LMNA (0.36) | LMNAMAPK1HTTCNR2CNR1 | |
| SCHEMBL28160427 | 0.94 | LMNA (0.35) | LMNAMAPK1HTTCNR2CNR1 | |
| SCHEMBL8452083 | 0.85 | LMNA (0.36) | LMNAMAPK1HTTCNR2CNR1 | |
| SCHEMBL2261535 | 0.82 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL988310 | 0.82 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL1238290 | 0.82 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL111657 | 0.82 | MAPK1 (0.38) | LMNAMAPK1HTTCNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625878-B2 | Sulfoalkyl ether-alkyl ether cyclodextrin derivatives | THE UNIVERSITY OF KANSAS (US) | 2009-12-01 | — | — | US | disclosed |
| US-20060258537-A1 | Sulfoalkyl ether-alkyl ether cyclodextrin derivatives | UNIVERSITY OF KANSAS | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258537-A1 | Sulfoalkyl ether-alkyl ether cyclodextrin derivatives | SELE, STS, EPCAM | LMNA 4070/4885MAPK1 2848/4885HTT 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.